Treatment of Uncomplicated Plasmodium vivax Malaria
Chloroquine (25 mg base/kg total dose over 3 days) remains the first-line treatment for uncomplicated P. vivax malaria in most settings, followed by primaquine (or tafenoquine) for radical cure to prevent relapse from liver hypnozoites 1.
Blood-Stage Treatment (Schizontocidal Therapy)
First-Line: Chloroquine
- Dosing: 25 mg base/kg total dose administered over 3 days
- Efficacy: Remains highly effective in most regions
- Geographic considerations: Use chloroquine EXCEPT in areas with documented resistance (Papua New Guinea, Indonesia, Sabah) where failure rates exceed 10% 1
Alternative: Artemisinin-Based Combination Therapies (ACTs)
When chloroquine resistance is suspected or confirmed, switch to ACTs:
Dihydroartemisinin-piperaquine (DHA-PPQ): Preferred ACT option
- Superior to chloroquine in preventing recurrences (HR 2.33 at day >42-63) 1
- Provides extended post-treatment prophylaxis due to piperaquine's long half-life
- Recent high-quality evidence from Brazil (2026) confirms excellent efficacy with recurrence rate of only 2.4% at day 42 when used alone, and 1.0% when combined with primaquine 2
Artemether-lumefantrine (AL): Acceptable alternative but inferior to DHA-PPQ (HR 2.07 at day 42) 1
Important caveat: In Europe, ACTs are only registered for P. falciparum malaria, making their use for P. vivax technically off-label 1
Radical Cure (Anti-Relapse Therapy)
Critical step: ALL P. vivax patients require treatment targeting liver hypnozoites to prevent relapse, which occurs in 9.3% of untreated cases 1.
Mandatory Pre-Treatment Testing
- G6PD testing is ESSENTIAL before administering 8-aminoquinolines (primaquine/tafenoquine)
- Use quantitative G6PD assays, especially in females who may have intermediate activity
- Risk of severe hemolysis in G6PD-deficient patients
Primaquine Regimens (based on G6PD status)
Normal G6PD activity (≥70%):
- Standard: 0.25 mg/kg/day for 14 days (total 3.5 mg/kg)
- Alternative: 0.5 mg/kg/day for 7 days (total 3.5 mg/kg) - WHO-endorsed 2022, improves adherence 3
- Efficacy: 80% risk reduction in relapse 1
Mild-moderate G6PD deficiency (>30% to <70% activity, non-Mediterranean variant):
- Weekly dosing: 0.75 mg/kg (maximum 45 mg) once weekly for 8 weeks
- Requires close monitoring for hemolysis 1
Severe G6PD deficiency or Mediterranean variant:
- Primaquine is CONTRAINDICATED
- Use suppressive therapy with chloroquine or hydroxychloroquine during pregnancy 4
Tafenoquine
- Single-dose alternative (not available in Europe)
- Requires G6PD activity ≥70%
- Only approved for coadministration with chloroquine by FDA 1
Absolute Contraindications for 8-Aminoquinolines
- Pregnancy (unknown fetal G6PD status)
- Breastfeeding
- Severe G6PD deficiency
- Management during pregnancy: Use suppressive chloroquine or hydroxychloroquine throughout pregnancy, then administer radical cure postpartum after confirming G6PD status 4
Key Clinical Pearls
Synergistic effect: Coadministration of primaquine with chloroquine boosts primaquine blood levels, enhancing efficacy 1
Post-artemisinin delayed hemolysis (PADH): Monitor for hemolysis up to day 14 after ACT treatment, though less common with oral therapy than IV artesunate 1
Treatment failure indicators: Recurrent parasitemia before day 28 suggests drug resistance; after day 28 may indicate relapse from hypnozoites or primaquine failure 5
Resistance patterns: Emerging mefloquine resistance in Cambodia and chloroquine resistance spreading in Oceania necessitate ongoing surveillance and treatment adaptation 6, 1